Arca
Skip to content
Tools
Tools

70S ribosome

Protein nucleic-acid complex in Mycobacterium tuberculosis that 4 drugs act on.

  • Drugs that act on it: 4
  • Approved: 3
  • In phases 1 to 3: 1
  • Sponsors: 2
  • Genes: 57

Who is on it, and how far along

Every drug ChEMBL records acting on RPLA, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 2
  • Protein or peptide 2

Approved3

  • Pyrazinamide
  • Capreomycin
  • Viomycin

Phase 30

    Phase 21

    • Sutezolid

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      • Sequella, Inc.125%

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: 70S ribosome inhibitor.
      PyrazinamideApproved—Small moleculeInhibitor51
      CapreomycinBoxed warningApprovedEpic PharmaProtein or peptideInhibitor1
      ViomycinApproved—Protein or peptideInhibitor0
      SutezolidPhase 2Sequella, Inc.Small moleculeInhibitor1

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 10 in all, from ClinicalTrials.gov.
      A Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without LevofloxacinPyrazinamidePhase 3RecruitingTuberculosis Research Centre, IndiaNov 18, 2026
      BRIGHT-Child TB: Short-Course Treatment for Non-Severe Pulmonary Tuberculosis in ChildrenPyrazinamidePhase 2RecruitingHuashan HospitalOct 26, 2026
      Study of Combinations of Novel Promising Drugs for Pulmonary TuberculosisPyrazinamidePhase 2Not yet recruitingTASK Applied ScienceAug 19, 2026
      A 6-Month MDR-END Plus Regimen for Rifampicin-Resistant TuberculosisPyrazinamidePhase 3Not yet recruitingSeoul National University HospitalJun 30, 2026
      Rifapentine-Based Shorter Regimens for Tuberculosis and TB Infection in KazakhstanPyrazinamide—Not yet recruitingPublic Union "Kazakhstan Association of Phthisiopulmonologists"Jun 25, 2026
      Re-evaluating the Duration in Children of TB TreatmentPyrazinamidePhase 2Not yet recruitingUniversity of Wisconsin, MadisonJun 18, 2026
      Short-Course Regimens for DS-PTB in AIDS PatientsPyrazinamideNot applicableNot yet recruitingShanghai Public Health Clinical CenterMay 27, 2026
      Collect Data From Patients Receiving Standardized Anti-tuberculosis Therapy, Collect Monitoring Data, and Evaluate Treatment Efficacy and Potential Adverse Reactions.Pyrazinamide—Enrolling by invitationBeijing Chest HospitalMay 26, 2026
      A Pan-TB Regimen Targeting Host and MicrobeSutezolidPhase 2 / Phase 3Active, not recruitingThe Aurum Institute NPCJan 17, 2023
      Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With TuberculosisCapreomycin—RecruitingBeijing Children's HospitalAug 10, 2018

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2363965, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.